Premium statistics

Industry-specific and extensively researched technical data (partially from exclusive partnerships).

A paid subscription is required for full access.

Revenue of Ablynx 2013-2017

Revenue of Ablynx from 2013 to 2017 (in 1,000 euros)

by Statista Research Department, last edited Oct 25, 2019
Revenue of Ablynx 2013-2017 This statistic illustrates the revenue of Ablynx from 2013 to 2017. Ablynx is a Belgian biopharmaceutical company engaged in the discovery and the development of nanobodies. In 2018, the French pharmaceutical company Sanofi acquired Ablynx for 3.9 billion euros. As of 2017, the revenue of Ablynx amounted to roughly 56 million euros, which is less than in the previous year, when Ablynx generated a revenue of approximately 85 million euros.
Show more

Revenue of Ablynx from 2013 to 2017 (in 1,000 euros)

Statista Accounts: Access All Statistics. Starting from $708 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account!

Premium Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$59 / Month *

Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.
Leading companies trust Statista:
Statista is a great source of knowledge, and pretty helpful to manage the daily work.
Christof Baron

Christof Baron
CEO, MindShare Germany

Statistics on "Pharmaceutical trends in Europe"
  • Overview
The most important statistics
  • European Pharmaceutical companies
  • Self-medication market
  • Employment
  • Clinical Trials
Discover Statista
Need help with using Statista for your research? Tutorials and first steps
Further Content: Statistics, Studies, and Topic Pages
Statista Accounts: Access All Statistics. Starting from $708 / Year
Learn more about how Statista can support your business.
Do you have any questions about our business solutions?

We provide you with detailed information about our Corporate Account.